PAVmed to Join Russell Microcap® Index
PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced that the
Company will join the Russell Microcap® Index at the conclusion of the Russell Indexes’ annual reconstitution, effective after the
U.S. market opens on June 26, 2017, according to a preliminary list of additions posted June 9, 2017 and again on June 16,
2017.
Membership in the Russell Microcap® Index provides automatic inclusion in the appropriate market indexes. FTSE Russell
determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“We are pleased that PAVmed will now be included in the Russell Microcap® Index,” said Lishan Aklog, M.D., PAVmed’s Chairman and
Chief Executive Officer. “We expect it will raise our visibility within the investment community as we continue our drive to
enhance shareholder value.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active
investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About FTSE Russell
FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a
true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. More than $12.5
trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers
and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London
Stock Exchange Group. For more information, visit ftserussell.com.
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to
advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical
device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory
pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™),
medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath™), tissue ablation and cardiovascular
intervention (Caldus™) and pediatric ear infections (DisappEAR™). The Company intends to further expand its pipeline through
engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of the
Company’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences include, among other things, the uncertainties inherent in
research and development, including the cost and time required advance our products to regulatory submission; whether regulatory
authorities will be satisfied with the design of and results from our preclinical studies; whether and when our products are
cleared by regulatory authorities; market acceptance of our products once cleared and commercialized; our ability to raise
additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body
to market any of its products. New risks and uncertainties may arise from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA, “Risk
Factors,” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be
updated in Part II, Item 1A, “Risk Factors” in any Quarterly Reports on Form 10-Q filed by us after our most recent Annual Report.
We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our
expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the forward-looking statements.
Investors
LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Media
RooneyPartners
Kate Barrette
(212) 223-0561
Kbarrette@rooneyco.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170622006105/en/